Nexalin Technology, Inc. (NXL) shareholders
Close on Nov 18, 2026Market cap $31.73MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alumni Capital LP Joint filing with Alumni Capital GP LLC (9.99%), Ashkan Mapar (9.99%) | 2,493,075 | 9.99% | 13G (passive) | Aug 19, 2026 |
| Greenlight Ventures, LLC | 1,385,246 | 5.60% | 13D (active) | Aug 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NXL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Peak6 LLC | 8,007 | 0.04% | $79.27K | −4,808 | 0.00% |
| Geode Capital Management, LLC | 4,653 | 0.02% | $46.06K | −3,581 | 0.00% |
| Vanguard Capital Management LLC | 4,218 | 0.02% | $41.76K | – | 0.00% |
| Citadel Advisors LLC | 2,513 | 0.01% | $24.88K | New | 0.00% |
| Jane Street Group, LLC | 2,184 | 0.01% | $21.61K | +1,834 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,713 | 0.01% | $16.96K | – | 0.00% |
| State Street Corp | 1,077 | 0.00% | $10.66K | – | 0.00% |
| UBS Group AG | 894 | 0.00% | $8.85K | +155 | 0.00% |
| Northern Trust Corp | 803 | 0.00% | $7.95K | – | 0.00% |
| Kovack Advisors, Inc. | 744 | 0.00% | $8.04K | −34 | 0.00% |
| StoneX Group Inc. | 450 | 0.00% | $5.41K | −314 | 0.00% |
| Raymond James Financial Inc | 403 | 0.00% | $3.99K | – | 0.00% |
| Integrated Investment Consultants, LLC | 333 | 0.00% | $3.30K | – | 0.00% |
| Osaic Holdings, Inc. | 70 | 0.00% | $693 | – | 0.00% |
| Tower Research Capital LLC (TRC) | 70 | 0.00% | $697 | – | 0.00% |
| Citigroup Inc | 49 | 0.00% | $481 | New | 0.00% |
| Wells Fargo & Company/Mn | 33 | 0.00% | $330 | – | 0.00% |
| Farther Finance Advisors, LLC | 33 | 0.00% | $330 | – | 0.00% |
| Federation des caisses Desjardins du Quebec | 29 | 0.00% | $288 | New | 0.00% |
| Barclays PLC | 8 | 0.00% | $80 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 20 | 0M | 0.1% | 4 / 2 | 4 / 7 | 0M | 0M |
| Q1 2026 | 23 | 0M | 0.2% | 9 / 3 | 7 / 4 | 0M | 0M |
| Q4 2025 | 19 | 0M | 0.3% | 5 / 9 | 1 / 6 | 0M | 0M |
| Q3 2025 | 20 | 0M | 0.1% | 4 / 4 | 6 / 4 | 0M | 0M |
| Q2 2025 | 21 | 0M | 0.2% | 9 / 4 | 0 / 5 | 0M | 0M |
| Q1 2025 | 17 | 0M | 0.1% | 3 / 3 | 4 / 5 | 0M | 0M |
| Q4 2024 | 19 | 0M | 0.1% | 11 / 6 | 1 / 7 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.1% | 8 / 1 | 3 / 5 | 0M | 0M |
| Q2 2024 | 13 | 0M | 0.0% | 10 / 2 | 1 / 2 | 0M | 0M |
| Q1 2024 | 5 | 0M | 0.0% | 2 / 1 | 0 / 0 | 0M | 0M |
| Q4 2023 | 3 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q3 2023 | 5 | 0M | 0.0% | 3 / 0 | 0 / 2 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark White | CEO, Director | 309,127 | 1.40% | Dec 23, 2025 |
| David Owens | Chief Medical Officer, Director | 191,252 | 0.87% | Dec 23, 2025 |
| Carolyn Hamby Shelton | Sr. VP - Quality - Regulatory | 54,000 | 0.25% | Dec 23, 2025 |
| Fleet Justin Van | CFO | 25,000 | 0.11% | Dec 23, 2025 |
| Alan Kazden | Director | 119,590 | 0.54% | Dec 23, 2025 |
| Ben Hu | Director | 381,261 | 1.73% | Dec 23, 2025 |
| Greenlight Ventures, LLC | 10% owner | 133,475 | 0.61% | Nov 17, 2026 |
| Marilyn Elson | – | 1,535,244 | 6.97% | Sep 30, 2025 |
| Leonard Osser | 10% owner | 2,453,821 | 11.14% | Sep 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alan Kazden Director | Sep 29, 2025 | Award | +36,459 | – | – | 119,590 |
| David Owens Chief Medical Officer, Director | Sep 29, 2025 | Award | +36,459 | – | – | 191,252 |
| Leonard Osser 10% owner | Sep 29, 2025 | Award | +83,333 | – | – | 1,618,577 |
| Ben Hu Director | Sep 29, 2025 | Award | +36,459 | – | – | 377,095 |
| Carolyn Hamby Shelton Sr. VP - Quality, Regulatory | Mar 12, 2025 | Buy | +6,000 | $2.20 | $13.20K | 30,000 |
| David Owens Chief Medical Officer, Director | Feb 4, 2025 | Buy | +1,000 | $3.10 | $3.10K | 155,793 |
| David Owens Chief Medical Officer, Director | Feb 4, 2025 | Buy | +1,000 | $2.98 | $2.98K | 154,793 |
| David Owens Chief Medical Officer, Director | Jan 28, 2025 | Buy | +1,500 | $2.70 | $4.05K | 153,793 |
| David Owens Chief Medical Officer, Director | Jan 23, 2025 | Buy | +1,000 | $2.70 | $2.70K | 152,293 |
| David Owens Chief Medical Officer, Director | Jan 13, 2025 | Buy | +2,000 | $2.50 | $5.00K | 151,293 |
| David Owens Chief Medical Officer, Director | Dec 20, 2024 | Buy | +1,000 | $2.75 | $2.75K | 149,293 |
| David Owens Chief Medical Officer, Director | Oct 28, 2024 | Buy | +500 | $2.19 | $1.10K | 148,293 |
| Carolyn Hamby Shelton Senior VP | Oct 14, 2024 | Buy | +24,000 | $0.85 | $20.40K | 24,000 |
| Ben Hu Director | Sep 30, 2024 | Award | +175,000 | – | – | 340,636 |
| Marilyn Elson 10% owner | Sep 30, 2024 | Award | +700,000 | – | – | 1,535,244 |
| Leslie Bernhard Director | Sep 30, 2024 | Award | +49,838 | – | – | 49,838 |
| Leonard Osser – | Sep 23, 2024 | Award | +700,000 | – | – | 1,535,244 |
| David Owens Chief Medical Officer, Director | Aug 13, 2024 | Buy | +1,000 | $0.95 | $950 | 147,793 |
| David Owens Chief Medical Officer, Director | Jun 28, 2024 | Buy | +1,000 | $1.75 | $1.75K | 146,793 |
| David Owens Chief Medical Officer, Director | Jun 18, 2024 | Buy | +1,619 | $0.71 | $1.15K | 145,793 |
| David Owens Chief Medical Officer, Director | Jun 10, 2024 | Buy | +1,000 | $0.62 | $620 | 144,174 |
| David Owens Chief Medical Officer, Director | Jun 10, 2024 | Buy | +2,000 | $0.65 | $1.30K | 143,174 |
| Leonard Osser – | Sep 28, 2022 | Buy | +9,500 | $1.12 | $10.64K | 835,244 |
| Alan Kazden Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 83,131 |
| Rick Morad Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 108,341 |
| Alan Kazden Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 89,131 |
| Rick Morad Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 107,989 |
| Leonard Osser – | Sep 16, 2022 | Buy | +36,000 | $4.15 | $149.40K | 825,744 |
| David Owens Chief Medical Officer, Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 141,174 |
| Mark White President/CEO, Director | Sep 16, 2022 | Buy | +2,500 | $4.15 | $10.38K | 289,627 |
| Mark White President/CEO, Director | Sep 15, 2022 | Buy | +25,000 | $4.15 | $103.75K | 309,127 |
| Mark White President/CEO, Director | Sep 15, 2022 | Buy | +25,000 | $4.15 | $103.75K | 289,627 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nexalin Technology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 377,263 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marilyn Elson Associate to Affiliate | Sep 10, 2025 | 23,150 | $403 | Sep 10, 2025 | Open Market Purchase |
See a number that looks wrong?